Drug Update · Cardiology

FDA Approves Baxdrostat for Resistant Hypertension: 9.8 mmHg SBP

July 15, 2026

FDA approval date

May 15, 2026

Indication

Treatment of hypertension in combination with other antihypertensive drugs in adults not adequately controlled on other agents

Recommended dose

2 mg orally once daily (1 mg once daily for patients at increased risk of hyperkalemia or hyponatremia) [2][11]

Primary efficacy (BaxHTN)

Placebo-corrected seated SBP reduction: 8.7 mmHg (1 mg) and 9.8 mmHg (2 mg) at Week 12 [8][11]

Most frequent adverse reaction

Hyperkalemia (10.2% with 2 mg; 6.6% with 1 mg; 2.5% placebo) [2][4]

Clinical Perspective

This approval affects prescribing clinicians in cardiology, primary care, and nephrology caring for adults with hypertension who remain inadequately controlled on other agents. The source-confirmed data support use of BAXFENDY as add-on therapy to lower seated systolic blood pressure, with recommended dosing of 2 mg once daily (1 mg once daily for patients at increased risk of hyperkalemia or hyponatremia) and structured laboratory monitoring for potassium and sodium per the label ^[1]^[4]. What remains unanswered from the provided excerpts is the long-term effect of baxdrostat on cardiovascular outcomes such as myocardial infarction or stroke?

Dr. Kavya Sharma · Cardiology

Baxdrostat (BAXFENDY) was approved by the U.S. Food and Drug Administration on May 15, 2026, for the treatment of hypertension in adults who are not adequately controlled on other agents, as add-on therapy to lower blood pressure ^[1]^[4]. Approval was based on the BaxHTN phase 3 program in which baxdrostat produced placebo-corrected reductions in seated systolic blood pressure of 8.7 mmHg with 1 mg and 9.8 mmHg with 2 mg at Week 12 compared with placebo (P<0.001) ^[3]^[4]. Clinicians should consult current prescribing information for complete dosing guidance.

Clinical Context

Baxdrostat is an aldosterone synthase inhibitor (inhibitor of human aldosterone synthase) developed by AstraZeneca Pharmaceuticals LP and marketed under the brand name BAXFENDY ^[1]^[4]. The U.S. label indicates baxdrostat is for use in combination with other antihypertensive drugs to lower blood pressure in adults who remain inadequately controlled on other agents ^[1]^[4]. The prescribing information notes that control of high blood pressure should be part of comprehensive cardiovascular risk management and that additional antihypertensive drugs are commonly required to achieve blood pressure goals ^[1]^[4]. The mechanism described in the label is inhibition of aldosterone synthase to decrease plasma aldosterone concentrations, which contributes to lowering blood pressure ^[4].

Key Findings

The BaxHTN trial showed baxdrostat reduced seated systolic blood pressure versus placebo: the placebo-corrected difference was -8.7 mmHg with 1 mg baxdrostat and -9.8 mmHg with 2 mg baxdrostat at Week 12 in adults with hypertension not adequately controlled on other antihypertensive medications ^[3]^[4].
Clinicians should consult current prescribing information for full dosing guidance.
In the BaxHTN trial the mean change from baseline in seated systolic blood pressure at 12 weeks was -14.5 mmHg with 1 mg baxdrostat, -15.7 mmHg with 2 mg baxdrostat, and -5.8 mmHg with placebo; the between-group least-squares mean differences versus placebo were -8.7 mmHg (1 mg) and -9.8 mmHg (2 mg) (P<0.001 for both) ^[3]^[4].
The BaxHTN program demonstrated maintenance of effect in a randomized withdrawal period: the mean difference from placebo during the 8-week randomized withdrawal was -5.1 mmHg (95% CI -8.3, -1.9; p=0.002) for BAXFENDY 2 mg ^[4].

Safety & Tolerability

Hyperkalemia was the most frequently reported adverse reaction and was more common with baxdrostat than placebo; hyperkalemia occurred in 10.2% of patients treated with BAXFENDY 2 mg, 6.6% with BAXFENDY 1 mg, and 2.5% with placebo during the 12-week randomized, double-blind periods ^[1]^[2]. Hyperkalemia led to permanent discontinuation in 8 (1.8%) patients in the BAXFENDY 2 mg group, 2 (0.6%) patients in the BAXFENDY 1 mg group, and none in the placebo group ^[1]^[2].
Clinicians should consult current prescribing information for full dosing guidance.
Laboratory abnormalities reported during the 12-week periods included increases in serum potassium (>5.5 mEq/L) in 12.2% of patients administered BAXFENDY 2 mg, 6.3% with BAXFENDY 1 mg, and 0.9% with placebo; decreases in serum sodium (<130 mEq/L) were reported in 3.7% (2 mg), 3.3% (1 mg), and 0.9% (placebo) ^[1]^[2].
Other adverse reactions reported ≥2% and greater than placebo included hypotension (3.6% for 2 mg, 2.1% for 1 mg, 0.5% placebo), hyponatremia (3.2% for 2 mg, 2.1% for 1 mg, 0.9% placebo), dizziness (2.9% for 2 mg, 3.0% for 1 mg, 0.9% placebo), and muscle spasms (2.9% for 2 mg, 1.8% for 1 mg, 0.7% placebo) ^[1]^[2].
A mean placebo-corrected decrease in estimated glomerular filtration rate (eGFR) at Week 12 was 8.0 mL/min/1.73 m2 for BAXFENDY 2 mg and 7.1 mL/min/1.73 m2 for BAXFENDY 1 mg; mean eGFR increased after discontinuation, consistent with a hemodynamic effect ^[1]^[2].

Study Design

The primary clinical efficacy data supporting approval derive from the BaxHTN multipart phase 3 program; in the BaxHTN trial 794 patients with systolic blood pressure ≥135 mmHg after a placebo run-in were randomized equally (1:1:1) to BAXFENDY 1 mg, BAXFENDY 2 mg, or placebo once daily during a 12-week double-blind treatment period ^[4]. Clinicians should consult current prescribing information for full dosing guidance. The primary endpoints were the change from baseline to Week 12 in seated office systolic blood pressure for BAXFENDY 2 mg versus placebo and for BAXFENDY 1 mg versus placebo; a randomized withdrawal double-blind period and open-label phases were also included in the multipart design ^[4].

FAQ

Q1 What is baxdrostat (BAXFENDY) approved for?

Baxdrostat (brand BAXFENDY) is approved for the treatment of hypertension as an add-on to other antihypertensive drugs to lower blood pressure in adults who are not adequately controlled on other agents. The U.S. label states that lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions, but notes there are no controlled trials demonstrating risk reduction of these events with BAXFENDY in the provided excerpts.

Q2 How does baxdrostat work?

Baxdrostat is an inhibitor of human aldosterone synthase; by inhibiting aldosterone synthase it decreases plasma aldosterone concentrations, which can reduce sodium and water retention and thereby lower blood pressure. The label describes baxdrostat as having higher potency and selectivity for aldosterone synthase compared to the related enzyme 11β-hydroxylase and notes that baxdrostat lowered aldosterone concentrations without affecting cortisol responses over a wide dose range in nonclinical and clinical studies.

Q3 What is the recommended dose of baxdrostat?

The recommended dosage of BAXFENDY is 2 mg orally once daily. For patients at increased risk of hyperkalemia or hyponatremia, the recommended dosage is 1 mg orally once daily. BAXFENDY may be taken with or without food and is available as 1 mg and 2 mg tablets; dosing precautions include assessing and periodically monitoring serum potassium and sodium before and during treatment as noted in the labeling. Clinicians should consult current prescribing information for complete dosing guidance.

Q4 What are the most common side effects of baxdrostat?

The most common adverse reaction reported more frequently than placebo and occurring in ≥5% of BAXFENDY-treated patients was hyperkalemia. Other adverse reactions reported in the randomized, double-blind periods at rates ≥2% and greater than placebo included hypotension, hyponatremia, dizziness, and muscle spasms. Laboratory abnormalities included increases in serum potassium (>5.5 mEq/L) and decreases in serum sodium (<130 mEq/L); specific incidence rates and discontinuation figures are reported in the prescribing information and clinical trial summaries.

FDA Approves Baxdrostat for Resistant Hypertension: 9.8 mmHg SBP

FDA Approves Baxdrostat for Resistant Hypertension: 9.8 mmHg SBP

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Cardiology in your inbox.

Related Clinical Updates

enlicitide Cuts LDL-C 56% and 59% in Phase 3 CORALreef Trials

Evolocumab Cuts LDL 63%; Alirocumab and Inclisiran: Data Guide

STRIDE: Semaglutide Increases Walking Distance 1.13-Fold in PAD with T2D

Verified HCP Portal